Hyperexcitability and translational phenotypes in a preclinical mouse model of SYNGAP1-related intellectual disability.

IF 5.8 1区 医学 Q1 PSYCHIATRY
Timothy A Fenton, Olivia Y Haouchine, Elizabeth B Hallam, Emily M Smith, Kiya C Jackson, Darlene Rahbarian, Cesar P Canales, Anna Adhikari, Alex S Nord, Roy Ben-Shalom, Jill L Silverman
{"title":"Hyperexcitability and translational phenotypes in a preclinical mouse model of SYNGAP1-related intellectual disability.","authors":"Timothy A Fenton, Olivia Y Haouchine, Elizabeth B Hallam, Emily M Smith, Kiya C Jackson, Darlene Rahbarian, Cesar P Canales, Anna Adhikari, Alex S Nord, Roy Ben-Shalom, Jill L Silverman","doi":"10.1038/s41398-024-03077-6","DOIUrl":null,"url":null,"abstract":"<p><p>Disruption of SYNGAP1 directly causes a genetically identifiable neurodevelopmental disorder (NDD) called SYNGAP1-related intellectual disability (SRID). Without functional SynGAP1 protein, individuals are developmentally delayed and have prominent features of intellectual disability (ID), motor impairments, and epilepsy. Over the past two decades, there have been numerous discoveries indicating the critical role of Syngap1. Several rodent models with a loss of Syngap1 have been engineered, identifying precise roles in neuronal structure and function, as well as key biochemical pathways key for synapse integrity. Homozygous loss of SYNGAP1/Syngap1 is lethal. Heterozygous mutations of Syngap1 result in a broad range of behavioral phenotypes. Our in vivo functional data, using the original mouse model from the Huganir laboratory, corroborated behaviors including robust hyperactivity and deficits in learning and memory in young adults. Furthermore, we described impairments in the domain of sleep, characterized using neurophysiological data that was collected with wireless, telemetric electroencephalography (EEG). Syngap1<sup>+/-</sup> mice exhibited elevated spiking events and spike trains, in addition to elevated power, most notably in the delta power frequency. For the first time, we illustrated that primary neurons from Syngap1<sup>+/-</sup> mice displayed: 1) increased network firing activity, 2) greater bursts, 3) and shorter inter-burst intervals between peaks, by utilizing high density microelectrode arrays (HD-MEA). Our work bridges in vitro electrophysiological neuronal activity and function with in vivo neurophysiological brain activity and function. These data elucidate quantitative, translational biomarkers in vivo and in vitro that can be utilized for the development and efficacy assessment of targeted treatments for SRID.</p>","PeriodicalId":23278,"journal":{"name":"Translational Psychiatry","volume":null,"pages":null},"PeriodicalIF":5.8000,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11447000/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41398-024-03077-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

Disruption of SYNGAP1 directly causes a genetically identifiable neurodevelopmental disorder (NDD) called SYNGAP1-related intellectual disability (SRID). Without functional SynGAP1 protein, individuals are developmentally delayed and have prominent features of intellectual disability (ID), motor impairments, and epilepsy. Over the past two decades, there have been numerous discoveries indicating the critical role of Syngap1. Several rodent models with a loss of Syngap1 have been engineered, identifying precise roles in neuronal structure and function, as well as key biochemical pathways key for synapse integrity. Homozygous loss of SYNGAP1/Syngap1 is lethal. Heterozygous mutations of Syngap1 result in a broad range of behavioral phenotypes. Our in vivo functional data, using the original mouse model from the Huganir laboratory, corroborated behaviors including robust hyperactivity and deficits in learning and memory in young adults. Furthermore, we described impairments in the domain of sleep, characterized using neurophysiological data that was collected with wireless, telemetric electroencephalography (EEG). Syngap1+/- mice exhibited elevated spiking events and spike trains, in addition to elevated power, most notably in the delta power frequency. For the first time, we illustrated that primary neurons from Syngap1+/- mice displayed: 1) increased network firing activity, 2) greater bursts, 3) and shorter inter-burst intervals between peaks, by utilizing high density microelectrode arrays (HD-MEA). Our work bridges in vitro electrophysiological neuronal activity and function with in vivo neurophysiological brain activity and function. These data elucidate quantitative, translational biomarkers in vivo and in vitro that can be utilized for the development and efficacy assessment of targeted treatments for SRID.

SYNGAP1相关智障临床前小鼠模型的过度兴奋和转化表型。
SYNGAP1中断会直接导致一种可遗传识别的神经发育障碍(NDD),即SYNGAP1相关智力障碍(SRID)。如果没有功能性的 SynGAP1 蛋白,患者就会发育迟缓,并具有智力障碍 (ID)、运动障碍和癫痫等显著特征。在过去二十年中,有许多发现表明了Syngap1的关键作用。目前已设计出多个缺失 Syngap1 的啮齿类动物模型,确定了其在神经元结构和功能中的精确作用,以及突触完整性的关键生化途径。SYNGAP1/Syngap1的同基因缺失是致命的。Syngap1的杂合突变会导致多种行为表型。我们使用 Huganir 实验室的原始小鼠模型所获得的体内功能数据证实了这些行为,包括年轻成人的过度活跃和学习与记忆缺陷。此外,我们还利用无线遥测脑电图(EEG)收集的神经生理学数据描述了睡眠障碍。Syngap1+/-小鼠表现出尖峰事件和尖峰序列的升高,此外还有功率的升高,最明显的是δ功率频率的升高。我们首次证明了 Syngap1+/- 小鼠的初级神经元表现出以下特征:通过使用高密度微电极阵列(HD-MEA),我们首次证明了 Syngap1+/- 小鼠的初级神经元显示出:1)更高的网络发射活动;2)更大的爆发;3)更短的峰值间爆发间隔。我们的工作将体外神经元电生理活动和功能与体内大脑神经生理活动和功能联系起来。这些数据阐明了体内和体外的定量转化生物标志物,可用于SRID靶向治疗的开发和疗效评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
11.50
自引率
2.90%
发文量
484
审稿时长
23 weeks
期刊介绍: Psychiatry has suffered tremendously by the limited translational pipeline. Nobel laureate Julius Axelrod''s discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of contemporary antidepressant treatment. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients. Translational Psychiatry bridges this gap by fostering and highlighting the pathway from discovery to clinical applications, healthcare and global health. We view translation broadly as the full spectrum of work that marks the pathway from discovery to global health, inclusive. The steps of translation that are within the scope of Translational Psychiatry include (i) fundamental discovery, (ii) bench to bedside, (iii) bedside to clinical applications (clinical trials), (iv) translation to policy and health care guidelines, (v) assessment of health policy and usage, and (vi) global health. All areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging and epidemiology are welcome as they contribute to enhance the field of translational psychiatry.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信